Company: CDT
Filing Date: 2025-12-12
Form Type: S-8 POS
Source: 0001493152-25-027522
Chunk: 6

Company: CDT Equity Inc.
Filing Date: 2025-12-12
Form: S-8 POS
Chunk 6
---
. You should also carefully read the information incorporated by reference into this Reoffer Prospectus, including our financial statements, and the exhibits to the registration statement of which this Reoffer Prospectus is a part.

Overview

CDT Equity Inc. is a data driven pharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. The Company has evolved into a broader, more agile platform that leverages artificial intelligence (“AI”), solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments.

Our strategy is centered on unlocking the untapped value of clinical-stage compounds, particularly those deprioritized by larger pharmaceutical companies with strong, supporting Phase I safety data. Through advanced co-crystallization and solid-form technologies developed at our Cambridge facilities, we improve drug properties and extend patent life by up to 20 years. In partnership with Sarborg Limited (“Sarborg”), we also apply AI-powered disease mapping to rapidly identify new therapeutic applications for existing compounds.

Our pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, and animal health. Ongoing in vitro and in vivo studies, guided by AI insights, are designed to support licensing and commercialization partnerships. We will seek an exit through third-party license deals following successful in vitro and in vivo pre-clinical trials, entering into agreements with third-parties to pursue further development, Food and Drug Administration (“FDA”) approval, commercialization and marketing of our assets.

Operating with a lean, asset-agnostic model, the Company prioritizes speed, adaptability, and capital efficiency. We avoid the cost burden of late-stage clinical trials, focusing instead on high-leverage development strategies.

Recent Developments

Reverse Stock Split

On October 8, 2025, the Company filed a certificate of amendment to its Second Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware to effectuate a 1-for-8 reverse stock split of the outstanding shares of the Company’s Common Stock (the “Reverse Stock Split”). At the Company’s Special Meeting of Stockholders on May 5, 2025, the stockholders approved future reverse stock splits and granted the Board of Directors (the “Board”) the authority to determine the exact split ratios and when to proceed with any such reverse stock splits. The Reverse Stock Split became effective on October 10, 2025, at 5:00 p.m., Eastern Time (the “Effective Time”) and